RxDoctor Payments Data

Whitney Powell, OD

Optometrist · Huntsville, ALNPI 1619629599

Payments from drug & device makers

$4,737in general payments, 2019–2025

Across 168 payments — averaging $28.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$756
  • Tarsus Pharmaceuticals, Inc.$595
  • Sun Pharmaceutical Industries Inc.$580
  • Oyster Point Pharma, Inc.$457
  • Biotissue Holdings Inc.$441
  • Bausch & Lomb Americas Inc.$407
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$4,737100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,737 in reported general payments places this provider in the 90th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$126,789
Medicare patients
545
Services billed
1,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost166$69,903
RestasisCyclosporine58$68,447
XdemvyLotilaner37$68,265
TyrvayaVarenicline Tartrate64$41,660
XiidraLifitegrast20$31,160
Cyclosporine24$16,283
VyzultaLatanoprostene Bunod19$7,042
Travoprost29$6,685
Latanoprost280$5,299
Alphagan PBrimonidine Tartrate14$4,318
Brimonidine Tartrate54$3,387
Loteprednol Etabonate17$2,168
Bimatoprost29$2,036
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$1,461
Prednisolone Acetate36$1,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$756$142,668238 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$595$68,26537 claims
Oyster Point Pharma, Inc.Tyrvaya$457$41,66064 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$407$38,20239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 749 optometrist providers in Alabama.

Other optometrist in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →